Factory 99% Dacomitinib Powder CAS 1110813-31-4 Chemical Intermediate Anti-Tumor Dacomitinib

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A540
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Name: Dacomitinib
• CAS: 1110813-31-4
• Appearance: White Powder
• Assay: 99%
• OEM: Available
• Sample: Available
• Suitable: Adult
• MOQ: 10g
• Function: Anti-Tumor
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

Product Name	Dacomitinib
Appearance	White Powder
CAS NO.	1110813-31-4
MF	C24H20FN3O4
Storage	Keep in a cool, dry, dark location

 

Dacomitinib is a chemical compound with the molecular formula C24H20FN3O4, which is not bolded here as per the instruction. It belongs to the class of kinase inhibitors, specifically targeting epidermal growthfactor receptor (EGFR) tyrosine kinases.

 

1. Cancer Treatment: Dacomitinib is primarily used in the treatment of certain types of cancer, particularly non-small cell lung cancer (NSCLC). It helps to inhibit the growth and spread of cancer cells by blocking the EGFR signaling pathway.
2. Targeted Therapy: As a targeted therapy, dacomitinib is more selective than traditional chemotherapy drugs, reducing the risk of harm to healthy cells while effectively attacking cancer cells.
3. Combination Therapy: Dacomitinib may also be used in combination with other cancer treatments, such as radiation therapy or surgery, to enhance overall treatment efficacy.

1. EGFR Inhibition: By binding to the EGFR tyrosine kinase domain, dacomitinib inhibits the activation of EGFR and subsequent signaling cascades that promote cell proliferation, survival, and migration.
2. Anti-tumor Activity: This inhibition leads to a reduction in tumor cell growth and survival, ultimately contributing to the regression of cancer tumors.
3. Improved Survival Rates: Clinical studies have shown that dacomitinib can improve progression-free survival and overall survival rates in patients with NSCLC, especially those with EGFR mutations.